Interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) integrate inflammatory and adipose signaling but also have direct vascular effects. We hypothesized that plasma levels of IL-6 and soluble tumor necrosis factor α receptor 2 (sol-TNFR2) would be related to coronary atherosclerosis beyond established risk factors and the metabolic syndrome.
Methods
We examined the association of IL-6 and sol-TNFR2 with metabolic syndrome, C-reactive protein (CRP), and coronary artery calcification (CAC) in 875 asymptomatic participants in the Study of Inherited Risk of Coronary Atherosclerosis.
Results
IL-6 levels were 56% higher (p < .001) and sol-TNFR2 levels 16% higher (p < .001) in subjects with metabolic syndrome compared with those without. Both cytokines were associated with CAC beyond age, gender, Framingham risk scores, family history, metabolic syndrome, and CRP (odds ratio and 95% confidence interval of higher CAC for 1 SD increase in log-transformed cytokine levels: 1.23 [1.06-1.43], p = .006 for IL-6 and 1.15 [1.01-1.31], p = .04 for sol-TNFR2). In fact, cytokine levels were independently associated with CAC scores in the subgroup with metabolic syndrome and were additive to the homeostasis model assessment of insulin resistance in predicting CAC.
Conclusions
Plasma IL-6 and sol-TNFR2 levels were independently associated with CAC, suggesting a role in integrating innate immune and adipose signaling in promoting atherosclerosis and cardiovascular risk. Measurement of their levels may facilitate cardiovascular risk prediction and targeting of therapeutic strategies.
ReavenGM.Banting lecture 1988. Role of insulin resistance in human disease. Diabetes1988;37:1595–607.
2.
RossR.Atherosclerosis-an inflammatory disease. N Engl J Med1999;340:115–26.
3.
FestaA, D'AgostinoRJr, HowardG, . Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation2000;102:42–7.
4.
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA2001;2852486–97.
5.
PearsonTA, MensahGA, AlexanderRW, . Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation2003;107:499–511.
6.
RajalaMW, SchererPE.Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology2003;144:3765–73.
7.
ReillyMP, RaderDJ.The metabolic syndrome: more than the sum of its parts?Circulation2003;108:1546–51.
8.
MollerDE.Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab2000;11:212–7.
9.
HotamisligilGS.Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord2003;27Suppl 3:S53–5.
10.
Mohamed-AliV, GoodrickS, RaweshA, . Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab1997;82:4196–200.
11.
BastardJP, MaachiM, VanNhieu JT, . Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab2002;87:2084–9.
12.
HuberSA, SakkinenP, ConzeD, . Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol1999;19:2364–7.
SchreyerSA, VickCM, LeBoeufRC.Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem2002;277:12364–8.
15.
BemelmansMH, van TitsLJ, BuurmanWA.Tumor necrosis factor: function, release and clearance. Crit Rev Immunol1996;16:1–11.
16.
Diez-RuizA, TilzGP, ZangerleR, . Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol1995;54:1–8.
17.
AderkaD.The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev1996;7:231–40.
18.
RidkerPM, RifaiN, StampferMJ, HennekensCH.Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation2000;101:1767–72.
19.
PaiJK, PischonT, MaJ, et al.Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med2004;351:2599–610.
20.
BlannAD, McCollumCN.Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation1998;22:483–91.
21.
RidkerPM, RifaiN, PfefferM, . Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation2000;101:2149–53.
22.
ReillyMP, WolfeML, LocalioAR, RaderDJ.C-reactive protein and coronary artery calcification: the Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). Arterioscler Thromb Vasc Biol2003;23:1851–6.
23.
ReillyMP, WolfeML, LocalioAR, RaderDJ.Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. Atherosclerosis2004;173:69–78.
24.
ReillyMP, WolfeML, RhodesT, . Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation2004;110:803–9.
25.
ReillyMP, WolfeML, DykhouseJ, . Intercellular adhesion molecule 1 (ICAM-1) gene variant is associated with coronary artery calcification independent of soluble ICAM-1 levels. J Invest Med2004;52:515–22.
26.
ReillyMP, LehrkeM, WolfeML, . Resistin is an inflammatory marker of atherosclerosis in humans. Circulation2005;111:932–9.
27.
WilsonPW, D'AgostinoRB, LevyD, . Prediction of coronary heart disease using risk factor categories. Circulation1998;97:1837–47.
28.
GrundySM, BrewerHBJr, CleemanJI, . Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation2004;109:433–8.
29.
MatthewsDR, HoskerJP, RudenskiAS, . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985;28:412–9.
30.
AgatstonAS, JanowitzWR, HildnerFJ, . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol1990;15:827–32.
31.
JamjoumLS, BielakLF, TurnerST, . Relationship of blood pressure measures with coronary artery calcification. Med Sci Monit2002;8CR775–81.
32.
RumbergerJA, BrundageBH, RaderDJ, KondosG.Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc1999;74:243–52.
33.
NewmanAB, NaydeckBL, WhittleJ, . Racial differences in coronary artery calcification in older adults. Arterioscler Thromb Vasc Biol2002;22:424–30.
34.
RaggiP, ShawLJ, BermanDS, CallisterTQ.Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol2004;43:1663–9.
35.
RidkerPM, BuringJE, CookNR, RifaiN. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation2003;107:391–7.
36.
SattarN, GawA, ScherbakovaO, . Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108:414–9.
37.
AlbertiKG, ZimmetPZ.Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med1998;15:539–53.
38.
FuV.Estimating generalized ordered logit models. Stata Technical Bulletin1998;44:27–30.
39.
NasirK, RaggiP, RumbergerJA, . Coronary artery calcium volume scores on electron beam tomography in 12,936 asymptomatic adults. Am J Cardiol2004;93:1146–9.
40.
PapanicolaouDA, VgontzasAN.Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab2000;85:1331–3.
41.
StomporT, PasowiczM, SullowiczW, . An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis2003;41:203–11.
42.
ChanJC, CheungJC, StehouwerCD, . The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome-an analysis by structural equation modelling. Int J Obes Relat Metab Disord2002;26:994–1008.
43.
JonesSA, Rose-JohnS.The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta2002;1592:251–63.
44.
PradhanAD, MansonJE, RifaiN, . C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA2001;286:327–34.
45.
LoppnowH, LibbyP.Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res1989;8:293–9.
46.
RusHG, VlaicuR, NiculescuF.Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis1996;127:263–71.
47.
LucG, BardJM, Juhan-VagueI. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol2003;23:1255–61.
48.
WallachD, VarfolomeevEE, MalininNL, . Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol1999;17:331–67.
49.
MukhopadhyayA, SuttlesJ, StoutRD, AggarwalBB.Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages. J Biol Chem2001;276:31906–12.
50.
AggarwalBB.Signalling pathways of the TNF superfofamily: a double-edged sword. Nat Rev Immunol2003;3:745–56.
ChuNF, SpiegelmanD, RifaiN, . Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men. Int J Obes Relat Metab Disord2000;24:1085–92.
53.
ChuNF, SpiegelmanD, HotamisligilGS, . Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis2001;157:495–503.
54.
UysalKT, WiesbrockSM, MarinoMW, HotamisligilGS.Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature1997;389:610–4.
55.
BobikA, KalininaN.Tumor necrosis factor receptor and ligand superfamily family members TNFRSF14 and LIGHT: new players in human atherogenesis. Arterioscler Thromb Vasc Biol2001;21:1873–5.
56.
BarathP, FishbeinMC, CaoJ, . Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol1990;65:297–302.
57.
KaartinenM, PenttilaA, KovanenPT.Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. Circulation1996;94:2787–92.
58.
IdelS, DanskyHM, BreslowJL.A20, a regulator of NFkappaB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc Natl Acad Sci U S A2003;100:14235–40.
59.
CollinsT, ReadMA, NeishAS, . Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. Faseb J1995;9:899–909.
60.
RedbergRF, RifaiN, GeeL, RidkerPM.Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol2000;36:39–43.
61.
HuntME, O'MalleyPG, VernalisMN, . C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J2001;141:206–10.
62.
WangTJ, LarsonMG, LevyD, . C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the. Framingham Heart Study Circulation2002;106:1189–91.
MautnerGC, MautnerSL, FroehlichJ, . Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation. Radiology1994;192:619–23.
65.
RumbergerJA, SchwartzRS, SimonsDB, . Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy. Am J Cardiol1994;73:1169–73.
66.
KondosGT, HoffJA, SevrukovA, . Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation2003;107:2571–6.
67.
PletcherMJ, TiceJA, PignoneM, BrownerWS.Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med2004;164:1285–92.
